11 research outputs found
PneumoADIP: An Example of Translational Research to Accelerate Pneumococcal Vaccination in Developing Countries
Historically, the introduction of new vaccines in developing countries
has been delayed due to lack of a coordinated effort to address both
demand and supply issues. The introduction of vaccines in developing
countries has been plagued by a vicious cycle of uncertain demand
leading to limited supply, which keeps prices relatively high and, in
turn, further increases the uncertainty of demand. The Pneumococcal
Vaccines Accelerated Development and Introduction Plan (PneumoADIP) is
an innovative approach designed to overcome this vicious cycle and to
help assure an affordable, sustainable supply of new pneumococcal
vaccines for developing countries. Translational research will play an
important role in achieving the goals of PneumoADIP by establishing the
burden of pneumococcal disease and the value of pneumococcal vaccines
at global and country levels. If successful, PneumoADIP will reduce the
uncertainty of demand, allow appropriate planning of supply, and
achieve adequate and affordable availability of product for the
introduction of pneumococcal vaccines. This model may provide a useful
example and valuable lessons for how a successful public-private
partnership can improve global health
An updated methodology to review developing-country vaccine manufacturer viability
In 1997, Milstien, Batson, and Meaney published “A Systematic Method for Evaluating the Potential Viability of Local Vaccine Producers.” The paper identified characteristics of successful vaccine manufacturers and developed a viability framework to evaluate their performance. This paper revisits the original study after two decades to determine the ability of the framework to predict manufacturer success. By reconstructing much of the original dataset and conducting in-depth interviews, the authors developed informed views on the continued viability of manufacturers in low- and middle-income country markets. Considering the marked changes in the market and technology landscape since 1997, the authors find the viability framework to be predictive and a useful lens through which to evaluate manufacturer success or failure. Of particular interest is how incumbent and potentially new developing-country vaccine manufacturers enter and sustain production in competitive international markets and how they integrate (or fail to integrate) new technology into the production process. Ultimately, most manufacturers will need to meet global quality standards to be viable. As governments and donors consider investments in vaccine producers, the updated viability factors will be a useful tool in evaluating the prospects of manufacturers over the mid to long term. The paper emphasizes that while up-front investments are important, other critical factors—including investments in a national regulatory authority, manufacturer independence, and ability to adapt and adopt new technology—are necessary to ensure viability
MOESM1 of Modeling the potential impact of emerging innovations on achievement of Sustainable Development Goals related to maternal, newborn, and child health
Additional file 1. Sources on epidemiologic data